Trials / Completed
CompletedNCT06068946
VK2735 for Weight Management Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Viking Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist |
| BIOLOGICAL | Placebo | Placebo comparator |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2024-02-27
- Completion
- 2024-04-02
- First posted
- 2023-10-05
- Last updated
- 2025-02-12
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06068946. Inclusion in this directory is not an endorsement.